Company intelligence

CODX

Co-Diagnostics, Inc. · NASDAQ · Healthcare

Price$1.25+1.63% · +$0.02

Market cap1.4MEquity value

P / E-0.1Trailing ratio

Volume0Latest session

Market data

CODX price chart

TradingView

Related signals

1 min delayed

Browse public CODX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CODXMar 25, 2026-10.35% since signal

Co-Diagnostics Expands TB Test Distribution, Market Opportunities Increase

Co-Diagnostics has initiated shipments for tuberculosis (TB) test studies in India, expanding its market reach across South Asia through a new partnership. This move aligns with WHO guidance and suggests strong growth potential, likely benefiting CODX's stock performance in the short term.

View signal analysis

CODXMar 20, 2026-2.26% since signal

Co-Diagnostics Expands South Asian Market Reach for PCR Products

Co-Diagnostics (CODX) has expanded its market presence in South Asia, increasing its total addressable market to $13 billion. This strategic move supports its goal of commercializing the CoSara PCR Pro and SARAGENE product lines, potentially enhancing overall revenue and market penetration.

View signal analysis

CODXFeb 24, 2025-16.50% since signal

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

CODX withdrew its FDA 510(k) application due to shelf‐life stability concerns. An enhanced COVID-19 test version will be submitted after additional clinical data is collected. The new submission incorporates updated PCR platform developments for improved manufacturing. Premarket price down 14.9%, indicating immediate investor concerns.

View signal analysis

Research